生物
内体
细胞质
免疫系统
细胞生物学
癌症研究
细胞培养
免疫学
分子生物学
细胞内
遗传学
作者
Subir Biswas,Gunjan Mandal,Carmen M. Anadon,Ricardo A. Chaurio,Luis Uriel Lopez-Bailon,Mate Z. Nagy,Jessica A. Mine,Kay Hänggi,Kimberly B. Sprenger,Patrick Innamarato,Carly M. Harro,John J. Powers,Joseph Johnson,Bin Fang,Mostafa Eysha,Xiaolin Nan,Roger Li,Bradford A. Perez,Tyler J. Curiel,Xiaoqing Yu,Paulo C. Rodríguez,José R. Conejo-Garcia
出处
期刊:Immunity
[Elsevier]
日期:2023-11-01
卷期号:56 (11): 2570-2583.e6
被引量:4
标识
DOI:10.1016/j.immuni.2023.09.013
摘要
Dimeric IgA (dIgA) can move through cells via the IgA/IgM polymeric immunoglobulin receptor (PIGR), which is expressed mainly on mucosal epithelia. Here, we studied the ability of dIgA to target commonly mutated cytoplasmic oncodrivers. Mutation-specific dIgA, but not IgG, neutralized KRASG12D within ovarian carcinoma cells and expelled this oncodriver from tumor cells. dIgA binding changed endosomal trafficking of KRASG12D from accumulation in recycling endosomes to aggregation in the early/late endosomes through which dIgA transcytoses. dIgA targeting of KRASG12D abrogated tumor cell proliferation in cell culture assays. In vivo, KRASG12D-specific dIgA1 limited the growth of KRASG12D-mutated ovarian and lung carcinomas in a manner dependent on CD8+ T cells. dIgA specific for IDH1R132H reduced colon cancer growth, demonstrating effective targeting of a cytoplasmic oncodriver not associated with surface receptors. dIgA targeting of KRASG12D restricted tumor growth more effectively than small-molecule KRASG12D inhibitors, supporting the potential of this approach for the treatment of human cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI